Loading stock data…
RARE
$26.46-0.38 (-1.42%)
Pre-Market$26.95+0.49 (+1.85%)· Last close May 13
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ultragenyx Pharmaceutical Inc. in the Healthcare sector is trading at $26.46. Wall Street consensus targets $52.75 (20 analysts), implying a +99.4% move over the next 12 months. The stock is currently 38% below its 52-week high of $42.37, remaining 4.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 76 is overbought against a weak tape. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +99.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 76 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$26.46
Potential Downside
0%
Whystock Fair Value$26.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$52.75+99.4%
Range$25.00 – $84.00
Fundamentals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
666.16%
Volume
Today's trading volume
1.09M
Recent News
Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses?
Ultragenyx Pharmaceutical Inc. reported past first-quarter 2026 results showing revenue of US$136 million versus US$139 million a year earlier, with a wider net loss of US$185 million and basic loss per share of US$1.84. Despite the larger loss and slightly lower revenue, management reaffirmed its 2026 revenue outlook of US$730 million to US$760 million and reiterated its goal of reaching profitability in 2027, setting up an important tension between current financial strain and future...
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.
Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary
Moby summary of Ultragenyx Pharmaceutical Inc.'s Q1 2026 earnings call
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights
Ultragenyx Pharmaceutical (NASDAQ:RARE) executives said the company is positioned for what Chief Executive Officer Emil Kakkis described as a “transformative” year, pointing to expectations for growing revenue, potential approvals for two gene therapies, and a key late-stage readout for its Angelman
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.